Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.

HIV clinical trials - 1 Jan 2000

Middleton T, Smith D, Larder B, Law M, Birch C

Abstract excerpt

PURPOSE: To relate baseline plasma HIV genotypic and virtual phenotypic antiretroviral drug susceptibility to subsequent virological response in patients receiving saquinavir (SQV)-enhancing therapy. Individuals were randomized to receive stavudine (d4T), SQV, and one of ritonavir, nelfinavir, or delavirdine to enhance SQV blood levels. METHOD: The protease and reverse transcriptase baseline sequences of 31...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Reverse Transcriptase

Share to Reverse Transcriptase Inhibitors

Share to Saquinavir

Share to Viral Load

Source

Identifiers

PMID: 11742431
DOI: 10.1310/YHGE-07Y8-T3XF-F6VT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.PMID 11742431Read ↗

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.Semantic proximity Read ↗

Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.Semantic proximity Read ↗

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.Semantic proximity Read ↗

Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.Semantic proximity Read ↗

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.Semantic proximity Read ↗

Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Rational approaches to resistance: using saquinavir.Semantic proximity Read ↗

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.Semantic proximity Read ↗

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.Semantic proximity Read ↗

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.Semantic proximity Read ↗

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.Semantic proximity Read ↗

Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.